nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—NR1I2—Ethinyl Estradiol—osteoporosis	0.147	0.216	CbGbCtD
Erlotinib—NR1I2—Estradiol—osteoporosis	0.0946	0.139	CbGbCtD
Erlotinib—SLCO2B1—Conjugated Estrogens—osteoporosis	0.0476	0.0699	CbGbCtD
Erlotinib—SLCO2B1—Estradiol—osteoporosis	0.0418	0.0613	CbGbCtD
Erlotinib—CYP1B1—Estradiol—osteoporosis	0.0361	0.053	CbGbCtD
Erlotinib—UGT1A1—Estradiol—osteoporosis	0.0312	0.0458	CbGbCtD
Erlotinib—ALB—Estropipate—osteoporosis	0.0285	0.0418	CbGbCtD
Erlotinib—CYP1A1—Cholecalciferol—osteoporosis	0.0197	0.0289	CbGbCtD
Erlotinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0196	0.0287	CbGbCtD
Erlotinib—ABCG2—Estradiol—osteoporosis	0.0172	0.0252	CbGbCtD
Erlotinib—CYP1A2—Estropipate—osteoporosis	0.0171	0.025	CbGbCtD
Erlotinib—CYP1A1—Estradiol—osteoporosis	0.0159	0.0233	CbGbCtD
Erlotinib—CYP2C8—Raloxifene—osteoporosis	0.0147	0.0216	CbGbCtD
Erlotinib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0142	0.0208	CbGbCtD
Erlotinib—ALB—Estradiol—osteoporosis	0.0118	0.0174	CbGbCtD
Erlotinib—CYP2C8—Cholecalciferol—osteoporosis	0.0113	0.0167	CbGbCtD
Erlotinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00961	0.0141	CbGbCtD
Erlotinib—CYP3A5—Estradiol—osteoporosis	0.00951	0.014	CbGbCtD
Erlotinib—CYP2C8—Estradiol—osteoporosis	0.00915	0.0134	CbGbCtD
Erlotinib—CYP3A4—Estropipate—osteoporosis	0.00893	0.0131	CbGbCtD
Erlotinib—CYP3A4—Calcitriol—osteoporosis	0.00893	0.0131	CbGbCtD
Erlotinib—CYP1A2—Conjugated Estrogens—osteoporosis	0.00807	0.0118	CbGbCtD
Erlotinib—CYP2D6—Cholecalciferol—osteoporosis	0.00724	0.0106	CbGbCtD
Erlotinib—CYP3A4—Ergocalciferol—osteoporosis	0.00714	0.0105	CbGbCtD
Erlotinib—CYP1A2—Estradiol—osteoporosis	0.00708	0.0104	CbGbCtD
Erlotinib—ABCB1—Conjugated Estrogens—osteoporosis	0.00705	0.0104	CbGbCtD
Erlotinib—ABCB1—Estradiol—osteoporosis	0.00619	0.00909	CbGbCtD
Erlotinib—CYP3A4—Raloxifene—osteoporosis	0.00596	0.00875	CbGbCtD
Erlotinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00576	0.00845	CbGbCtD
Erlotinib—CYP3A4—Cholecalciferol—osteoporosis	0.0046	0.00675	CbGbCtD
Erlotinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00423	0.0062	CbGbCtD
Erlotinib—CYP3A4—Estradiol—osteoporosis	0.00371	0.00544	CbGbCtD
Erlotinib—MKNK1—Estradiol—Estropipate—osteoporosis	0.00133	0.364	CbGdCrCtD
Erlotinib—MKNK1—Estradiol—Conjugated Estrogens—osteoporosis	0.00101	0.276	CbGdCrCtD
Erlotinib—MKNK1—Estradiol—Ethinyl Estradiol—osteoporosis	0.000845	0.232	CbGdCrCtD
Erlotinib—ORM1—vertebral column—osteoporosis	0.000793	0.199	CbGeAlD
Erlotinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000463	0.127	CbGdCrCtD
Erlotinib—TNK1—uterus—osteoporosis	0.000314	0.0787	CbGeAlD
Erlotinib—EGFR—uterus—osteoporosis	0.000252	0.063	CbGeAlD
Erlotinib—ULK3—uterus—osteoporosis	0.000233	0.0584	CbGeAlD
Erlotinib—FLT3—bone marrow—osteoporosis	0.000229	0.0574	CbGeAlD
Erlotinib—SLK—uterus—osteoporosis	0.000208	0.052	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—osteoporosis	0.000207	0.0519	CbGeAlD
Erlotinib—Infection—Risedronate—osteoporosis	0.000204	0.00107	CcSEcCtD
Erlotinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000204	0.00107	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000204	0.00107	CcSEcCtD
Erlotinib—Arthralgia—Pamidronate—osteoporosis	0.000203	0.00107	CcSEcCtD
Erlotinib—Myalgia—Pamidronate—osteoporosis	0.000203	0.00107	CcSEcCtD
Erlotinib—Back pain—Conjugated Estrogens—osteoporosis	0.000203	0.00107	CcSEcCtD
Erlotinib—Epistaxis—Estradiol—osteoporosis	0.000203	0.00106	CcSEcCtD
Erlotinib—Anxiety—Pamidronate—osteoporosis	0.000203	0.00106	CcSEcCtD
Erlotinib—Body temperature increased—Alendronate—osteoporosis	0.000202	0.00106	CcSEcCtD
Erlotinib—Abdominal pain—Alendronate—osteoporosis	0.000202	0.00106	CcSEcCtD
Erlotinib—Shock—Risedronate—osteoporosis	0.000202	0.00106	CcSEcCtD
Erlotinib—Nervous system disorder—Risedronate—osteoporosis	0.000201	0.00105	CcSEcCtD
Erlotinib—Skin disorder—Risedronate—osteoporosis	0.000199	0.00104	CcSEcCtD
Erlotinib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000199	0.00104	CcSEcCtD
Erlotinib—Abdominal pain—Raloxifene—osteoporosis	0.000199	0.00104	CcSEcCtD
Erlotinib—Body temperature increased—Raloxifene—osteoporosis	0.000199	0.00104	CcSEcCtD
Erlotinib—ULK3—bone marrow—osteoporosis	0.000198	0.0495	CbGeAlD
Erlotinib—Abdominal pain—Ibandronate—osteoporosis	0.000197	0.00103	CcSEcCtD
Erlotinib—Body temperature increased—Ibandronate—osteoporosis	0.000197	0.00103	CcSEcCtD
Erlotinib—Syncope—Zoledronate—osteoporosis	0.000196	0.00103	CcSEcCtD
Erlotinib—Oedema—Pamidronate—osteoporosis	0.000195	0.00102	CcSEcCtD
Erlotinib—Haemoglobin—Estradiol—osteoporosis	0.000194	0.00102	CcSEcCtD
Erlotinib—Infection—Pamidronate—osteoporosis	0.000194	0.00102	CcSEcCtD
Erlotinib—Haemorrhage—Estradiol—osteoporosis	0.000193	0.00101	CcSEcCtD
Erlotinib—Hepatitis—Estradiol—osteoporosis	0.000193	0.00101	CcSEcCtD
Erlotinib—Body temperature increased—Calcitriol—osteoporosis	0.000193	0.00101	CcSEcCtD
Erlotinib—Abdominal pain—Calcitriol—osteoporosis	0.000193	0.00101	CcSEcCtD
Erlotinib—Shock—Pamidronate—osteoporosis	0.000192	0.00101	CcSEcCtD
Erlotinib—Loss of consciousness—Zoledronate—osteoporosis	0.000192	0.00101	CcSEcCtD
Erlotinib—Nervous system disorder—Pamidronate—osteoporosis	0.000191	0.001	CcSEcCtD
Erlotinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000191	0.001	CcSEcCtD
Erlotinib—Urinary tract disorder—Estradiol—osteoporosis	0.000191	0.001	CcSEcCtD
Erlotinib—Vomiting—Etidronic acid—osteoporosis	0.000191	0.001	CcSEcCtD
Erlotinib—Cough—Zoledronate—osteoporosis	0.00019	0.000998	CcSEcCtD
Erlotinib—Connective tissue disorder—Estradiol—osteoporosis	0.00019	0.000995	CcSEcCtD
Erlotinib—Urethral disorder—Estradiol—osteoporosis	0.000189	0.000992	CcSEcCtD
Erlotinib—Rash—Etidronic acid—osteoporosis	0.000189	0.000991	CcSEcCtD
Erlotinib—Dermatitis—Etidronic acid—osteoporosis	0.000189	0.00099	CcSEcCtD
Erlotinib—Syncope—Conjugated Estrogens—osteoporosis	0.000188	0.000988	CcSEcCtD
Erlotinib—Headache—Etidronic acid—osteoporosis	0.000188	0.000985	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000187	0.000979	CcSEcCtD
Erlotinib—Asthenia—Estropipate—osteoporosis	0.000186	0.000976	CcSEcCtD
Erlotinib—MKNK1—bone marrow—osteoporosis	0.000186	0.0466	CbGeAlD
Erlotinib—Anorexia—Pamidronate—osteoporosis	0.000186	0.000974	CcSEcCtD
Erlotinib—Myalgia—Zoledronate—osteoporosis	0.000186	0.000974	CcSEcCtD
Erlotinib—Chest pain—Zoledronate—osteoporosis	0.000186	0.000974	CcSEcCtD
Erlotinib—Arthralgia—Zoledronate—osteoporosis	0.000186	0.000974	CcSEcCtD
Erlotinib—Insomnia—Risedronate—osteoporosis	0.000186	0.000972	CcSEcCtD
Erlotinib—Anxiety—Zoledronate—osteoporosis	0.000185	0.00097	CcSEcCtD
Erlotinib—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000185	0.000968	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000185	0.000967	CcSEcCtD
Erlotinib—Pruritus—Estropipate—osteoporosis	0.000184	0.000962	CcSEcCtD
Erlotinib—Asthenia—Alendronate—osteoporosis	0.000183	0.000961	CcSEcCtD
Erlotinib—Cough—Conjugated Estrogens—osteoporosis	0.000183	0.000961	CcSEcCtD
Erlotinib—Dyspnoea—Risedronate—osteoporosis	0.000183	0.000958	CcSEcCtD
Erlotinib—Erythema multiforme—Estradiol—osteoporosis	0.000183	0.000957	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000182	0.000952	CcSEcCtD
Erlotinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000181	0.000951	CcSEcCtD
Erlotinib—Pruritus—Alendronate—osteoporosis	0.000181	0.000948	CcSEcCtD
Erlotinib—Dyspepsia—Risedronate—osteoporosis	0.000181	0.000946	CcSEcCtD
Erlotinib—Eye disorder—Estradiol—osteoporosis	0.000181	0.000946	CcSEcCtD
Erlotinib—STK10—uterus—osteoporosis	0.00018	0.0452	CbGeAlD
Erlotinib—Constipation—Ethinyl Estradiol—osteoporosis	0.00018	0.000943	CcSEcCtD
Erlotinib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000179	0.000938	CcSEcCtD
Erlotinib—Chest pain—Conjugated Estrogens—osteoporosis	0.000179	0.000938	CcSEcCtD
Erlotinib—Myalgia—Conjugated Estrogens—osteoporosis	0.000179	0.000938	CcSEcCtD
Erlotinib—Asthenia—Ibandronate—osteoporosis	0.000179	0.000936	CcSEcCtD
Erlotinib—Anxiety—Conjugated Estrogens—osteoporosis	0.000178	0.000934	CcSEcCtD
Erlotinib—Nausea—Etidronic acid—osteoporosis	0.000178	0.000934	CcSEcCtD
Erlotinib—Oedema—Zoledronate—osteoporosis	0.000178	0.000933	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000178	0.000931	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000178	0.000931	CcSEcCtD
Erlotinib—Diarrhoea—Estropipate—osteoporosis	0.000178	0.000931	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000177	0.000928	CcSEcCtD
Erlotinib—Infection—Zoledronate—osteoporosis	0.000177	0.000927	CcSEcCtD
Erlotinib—Fatigue—Risedronate—osteoporosis	0.000177	0.000927	CcSEcCtD
Erlotinib—Insomnia—Pamidronate—osteoporosis	0.000176	0.000924	CcSEcCtD
Erlotinib—Pruritus—Ibandronate—osteoporosis	0.000176	0.000923	CcSEcCtD
Erlotinib—SLK—bone marrow—osteoporosis	0.000176	0.0441	CbGeAlD
Erlotinib—Pain—Risedronate—osteoporosis	0.000175	0.000919	CcSEcCtD
Erlotinib—Constipation—Risedronate—osteoporosis	0.000175	0.000919	CcSEcCtD
Erlotinib—Shock—Zoledronate—osteoporosis	0.000175	0.000918	CcSEcCtD
Erlotinib—Diarrhoea—Alendronate—osteoporosis	0.000175	0.000917	CcSEcCtD
Erlotinib—Asthenia—Calcitriol—osteoporosis	0.000175	0.000916	CcSEcCtD
Erlotinib—Nervous system disorder—Zoledronate—osteoporosis	0.000175	0.000915	CcSEcCtD
Erlotinib—Thrombocytopenia—Zoledronate—osteoporosis	0.000174	0.000914	CcSEcCtD
Erlotinib—Mediastinal disorder—Estradiol—osteoporosis	0.000174	0.000912	CcSEcCtD
Erlotinib—Dyspnoea—Pamidronate—osteoporosis	0.000174	0.000911	CcSEcCtD
Erlotinib—Chills—Estradiol—osteoporosis	0.000173	0.000908	CcSEcCtD
Erlotinib—Skin disorder—Zoledronate—osteoporosis	0.000173	0.000907	CcSEcCtD
Erlotinib—Pruritus—Calcitriol—osteoporosis	0.000172	0.000903	CcSEcCtD
Erlotinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000172	0.000902	CcSEcCtD
Erlotinib—Diarrhoea—Raloxifene—osteoporosis	0.000172	0.000901	CcSEcCtD
Erlotinib—Dyspepsia—Pamidronate—osteoporosis	0.000172	0.000899	CcSEcCtD
Erlotinib—Dizziness—Estropipate—osteoporosis	0.000172	0.000899	CcSEcCtD
Erlotinib—Oedema—Conjugated Estrogens—osteoporosis	0.000172	0.000899	CcSEcCtD
Erlotinib—Alopecia—Estradiol—osteoporosis	0.000171	0.000895	CcSEcCtD
Erlotinib—Infection—Conjugated Estrogens—osteoporosis	0.00017	0.000893	CcSEcCtD
Erlotinib—Diarrhoea—Ibandronate—osteoporosis	0.00017	0.000892	CcSEcCtD
Erlotinib—Anorexia—Zoledronate—osteoporosis	0.00017	0.00089	CcSEcCtD
Erlotinib—Decreased appetite—Pamidronate—osteoporosis	0.00017	0.000888	CcSEcCtD
Erlotinib—Mental disorder—Estradiol—osteoporosis	0.000169	0.000887	CcSEcCtD
Erlotinib—Dizziness—Alendronate—osteoporosis	0.000169	0.000886	CcSEcCtD
Erlotinib—Shock—Conjugated Estrogens—osteoporosis	0.000169	0.000884	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000168	0.000882	CcSEcCtD
Erlotinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000168	0.000881	CcSEcCtD
Erlotinib—Malnutrition—Estradiol—osteoporosis	0.000168	0.000881	CcSEcCtD
Erlotinib—Erythema—Estradiol—osteoporosis	0.000168	0.000881	CcSEcCtD
Erlotinib—Fatigue—Pamidronate—osteoporosis	0.000168	0.000881	CcSEcCtD
Erlotinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000168	0.000879	CcSEcCtD
Erlotinib—Constipation—Pamidronate—osteoporosis	0.000167	0.000874	CcSEcCtD
Erlotinib—Pain—Pamidronate—osteoporosis	0.000167	0.000874	CcSEcCtD
Erlotinib—Diarrhoea—Calcitriol—osteoporosis	0.000167	0.000874	CcSEcCtD
Erlotinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000167	0.000873	CcSEcCtD
Erlotinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000166	0.000872	CcSEcCtD
Erlotinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000166	0.000872	CcSEcCtD
Erlotinib—Dizziness—Raloxifene—osteoporosis	0.000166	0.000871	CcSEcCtD
Erlotinib—Flatulence—Estradiol—osteoporosis	0.000166	0.000868	CcSEcCtD
Erlotinib—Vomiting—Estropipate—osteoporosis	0.000165	0.000865	CcSEcCtD
Erlotinib—Dizziness—Ibandronate—osteoporosis	0.000165	0.000863	CcSEcCtD
Erlotinib—Rash—Estropipate—osteoporosis	0.000164	0.000858	CcSEcCtD
Erlotinib—Dermatitis—Estropipate—osteoporosis	0.000164	0.000857	CcSEcCtD
Erlotinib—Anorexia—Conjugated Estrogens—osteoporosis	0.000164	0.000857	CcSEcCtD
Erlotinib—Back pain—Estradiol—osteoporosis	0.000163	0.000853	CcSEcCtD
Erlotinib—Headache—Estropipate—osteoporosis	0.000163	0.000852	CcSEcCtD
Erlotinib—Vomiting—Alendronate—osteoporosis	0.000163	0.000852	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000162	0.00085	CcSEcCtD
Erlotinib—Body temperature increased—Risedronate—osteoporosis	0.000162	0.00085	CcSEcCtD
Erlotinib—Abdominal pain—Risedronate—osteoporosis	0.000162	0.00085	CcSEcCtD
Erlotinib—Rash—Alendronate—osteoporosis	0.000161	0.000845	CcSEcCtD
Erlotinib—Insomnia—Zoledronate—osteoporosis	0.000161	0.000844	CcSEcCtD
Erlotinib—Dermatitis—Alendronate—osteoporosis	0.000161	0.000844	CcSEcCtD
Erlotinib—Headache—Alendronate—osteoporosis	0.00016	0.000839	CcSEcCtD
Erlotinib—Vomiting—Raloxifene—osteoporosis	0.00016	0.000838	CcSEcCtD
Erlotinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000159	0.000836	CcSEcCtD
Erlotinib—Dyspnoea—Zoledronate—osteoporosis	0.000159	0.000832	CcSEcCtD
Erlotinib—Rash—Raloxifene—osteoporosis	0.000159	0.000831	CcSEcCtD
Erlotinib—Dermatitis—Raloxifene—osteoporosis	0.000158	0.00083	CcSEcCtD
Erlotinib—Vomiting—Ibandronate—osteoporosis	0.000158	0.000829	CcSEcCtD
Erlotinib—Headache—Raloxifene—osteoporosis	0.000158	0.000825	CcSEcCtD
Erlotinib—Rash—Ibandronate—osteoporosis	0.000157	0.000822	CcSEcCtD
Erlotinib—Dermatitis—Ibandronate—osteoporosis	0.000157	0.000822	CcSEcCtD
Erlotinib—Dyspepsia—Zoledronate—osteoporosis	0.000157	0.000822	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000156	0.000819	CcSEcCtD
Erlotinib—Headache—Ibandronate—osteoporosis	0.000156	0.000817	CcSEcCtD
Erlotinib—Insomnia—Conjugated Estrogens—osteoporosis	0.000155	0.000813	CcSEcCtD
Erlotinib—Vomiting—Calcitriol—osteoporosis	0.000155	0.000812	CcSEcCtD
Erlotinib—Decreased appetite—Zoledronate—osteoporosis	0.000155	0.000811	CcSEcCtD
Erlotinib—Nausea—Estropipate—osteoporosis	0.000154	0.000808	CcSEcCtD
Erlotinib—Body temperature increased—Pamidronate—osteoporosis	0.000154	0.000808	CcSEcCtD
Erlotinib—Abdominal pain—Pamidronate—osteoporosis	0.000154	0.000808	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000154	0.000806	CcSEcCtD
Erlotinib—Rash—Calcitriol—osteoporosis	0.000154	0.000805	CcSEcCtD
Erlotinib—Fatigue—Zoledronate—osteoporosis	0.000154	0.000805	CcSEcCtD
Erlotinib—Dermatitis—Calcitriol—osteoporosis	0.000154	0.000804	CcSEcCtD
Erlotinib—STK10—bone marrow—osteoporosis	0.000153	0.0384	CbGeAlD
Erlotinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000153	0.000801	CcSEcCtD
Erlotinib—Headache—Calcitriol—osteoporosis	0.000153	0.0008	CcSEcCtD
Erlotinib—Constipation—Zoledronate—osteoporosis	0.000152	0.000798	CcSEcCtD
Erlotinib—Pain—Zoledronate—osteoporosis	0.000152	0.000798	CcSEcCtD
Erlotinib—Nausea—Alendronate—osteoporosis	0.000152	0.000796	CcSEcCtD
Erlotinib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000151	0.000791	CcSEcCtD
Erlotinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000151	0.000791	CcSEcCtD
Erlotinib—Syncope—Estradiol—osteoporosis	0.000151	0.00079	CcSEcCtD
Erlotinib—Nausea—Raloxifene—osteoporosis	0.000149	0.000783	CcSEcCtD
Erlotinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000149	0.000781	CcSEcCtD
Erlotinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000149	0.00078	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000148	0.000776	CcSEcCtD
Erlotinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000148	0.000775	CcSEcCtD
Erlotinib—Nausea—Ibandronate—osteoporosis	0.000148	0.000775	CcSEcCtD
Erlotinib—Loss of consciousness—Estradiol—osteoporosis	0.000148	0.000775	CcSEcCtD
Erlotinib—Asthenia—Risedronate—osteoporosis	0.000147	0.000771	CcSEcCtD
Erlotinib—Cough—Estradiol—osteoporosis	0.000147	0.000769	CcSEcCtD
Erlotinib—Constipation—Conjugated Estrogens—osteoporosis	0.000147	0.000769	CcSEcCtD
Erlotinib—Pain—Conjugated Estrogens—osteoporosis	0.000147	0.000769	CcSEcCtD
Erlotinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000146	0.000763	CcSEcCtD
Erlotinib—Pruritus—Risedronate—osteoporosis	0.000145	0.000761	CcSEcCtD
Erlotinib—Nausea—Calcitriol—osteoporosis	0.000145	0.000758	CcSEcCtD
Erlotinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000144	0.000754	CcSEcCtD
Erlotinib—Arthralgia—Estradiol—osteoporosis	0.000143	0.00075	CcSEcCtD
Erlotinib—Chest pain—Estradiol—osteoporosis	0.000143	0.00075	CcSEcCtD
Erlotinib—Myalgia—Estradiol—osteoporosis	0.000143	0.00075	CcSEcCtD
Erlotinib—Anxiety—Estradiol—osteoporosis	0.000143	0.000748	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000142	0.000745	CcSEcCtD
Erlotinib—Abdominal pain—Zoledronate—osteoporosis	0.000141	0.000738	CcSEcCtD
Erlotinib—Body temperature increased—Zoledronate—osteoporosis	0.000141	0.000738	CcSEcCtD
Erlotinib—Diarrhoea—Risedronate—osteoporosis	0.00014	0.000735	CcSEcCtD
Erlotinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00014	0.000735	CcSEcCtD
Erlotinib—Asthenia—Pamidronate—osteoporosis	0.00014	0.000733	CcSEcCtD
Erlotinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000139	0.000729	CcSEcCtD
Erlotinib—Pruritus—Pamidronate—osteoporosis	0.000138	0.000723	CcSEcCtD
Erlotinib—Oedema—Estradiol—osteoporosis	0.000137	0.000719	CcSEcCtD
Erlotinib—Infection—Estradiol—osteoporosis	0.000136	0.000715	CcSEcCtD
Erlotinib—Dizziness—Risedronate—osteoporosis	0.000136	0.000711	CcSEcCtD
Erlotinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000136	0.00071	CcSEcCtD
Erlotinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000136	0.00071	CcSEcCtD
Erlotinib—Shock—Estradiol—osteoporosis	0.000135	0.000708	CcSEcCtD
Erlotinib—Nervous system disorder—Estradiol—osteoporosis	0.000135	0.000705	CcSEcCtD
Erlotinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000134	0.000701	CcSEcCtD
Erlotinib—Diarrhoea—Pamidronate—osteoporosis	0.000133	0.000699	CcSEcCtD
Erlotinib—Skin disorder—Estradiol—osteoporosis	0.000133	0.000699	CcSEcCtD
Erlotinib—Rash—Ethinyl Estradiol—osteoporosis	0.000133	0.000695	CcSEcCtD
Erlotinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000133	0.000694	CcSEcCtD
Erlotinib—Headache—Ethinyl Estradiol—osteoporosis	0.000132	0.000691	CcSEcCtD
Erlotinib—Vomiting—Risedronate—osteoporosis	0.00013	0.000683	CcSEcCtD
Erlotinib—Rash—Risedronate—osteoporosis	0.000129	0.000678	CcSEcCtD
Erlotinib—Dermatitis—Risedronate—osteoporosis	0.000129	0.000677	CcSEcCtD
Erlotinib—Dizziness—Pamidronate—osteoporosis	0.000129	0.000676	CcSEcCtD
Erlotinib—Headache—Risedronate—osteoporosis	0.000129	0.000673	CcSEcCtD
Erlotinib—Asthenia—Zoledronate—osteoporosis	0.000128	0.00067	CcSEcCtD
Erlotinib—Pruritus—Zoledronate—osteoporosis	0.000126	0.00066	CcSEcCtD
Erlotinib—SLCO2B1—uterus—osteoporosis	0.000125	0.0314	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000125	0.000655	CcSEcCtD
Erlotinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000125	0.000655	CcSEcCtD
Erlotinib—ABL1—uterus—osteoporosis	0.000124	0.0312	CbGeAlD
Erlotinib—Insomnia—Estradiol—osteoporosis	0.000124	0.000651	CcSEcCtD
Erlotinib—Vomiting—Pamidronate—osteoporosis	0.000124	0.00065	CcSEcCtD
Erlotinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000123	0.000645	CcSEcCtD
Erlotinib—Rash—Pamidronate—osteoporosis	0.000123	0.000644	CcSEcCtD
Erlotinib—Dermatitis—Pamidronate—osteoporosis	0.000123	0.000644	CcSEcCtD
Erlotinib—Dyspnoea—Estradiol—osteoporosis	0.000122	0.000641	CcSEcCtD
Erlotinib—Headache—Pamidronate—osteoporosis	0.000122	0.00064	CcSEcCtD
Erlotinib—Diarrhoea—Zoledronate—osteoporosis	0.000122	0.000639	CcSEcCtD
Erlotinib—Nausea—Risedronate—osteoporosis	0.000122	0.000638	CcSEcCtD
Erlotinib—Pruritus—Conjugated Estrogens—osteoporosis	0.000121	0.000636	CcSEcCtD
Erlotinib—Dyspepsia—Estradiol—osteoporosis	0.000121	0.000633	CcSEcCtD
Erlotinib—Decreased appetite—Estradiol—osteoporosis	0.000119	0.000625	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000119	0.000621	CcSEcCtD
Erlotinib—Fatigue—Estradiol—osteoporosis	0.000118	0.00062	CcSEcCtD
Erlotinib—Dizziness—Zoledronate—osteoporosis	0.000118	0.000617	CcSEcCtD
Erlotinib—Pain—Estradiol—osteoporosis	0.000117	0.000615	CcSEcCtD
Erlotinib—Constipation—Estradiol—osteoporosis	0.000117	0.000615	CcSEcCtD
Erlotinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000117	0.000615	CcSEcCtD
Erlotinib—Nausea—Pamidronate—osteoporosis	0.000116	0.000607	CcSEcCtD
Erlotinib—Dizziness—Conjugated Estrogens—osteoporosis	0.000113	0.000594	CcSEcCtD
Erlotinib—Vomiting—Zoledronate—osteoporosis	0.000113	0.000593	CcSEcCtD
Erlotinib—Rash—Zoledronate—osteoporosis	0.000112	0.000589	CcSEcCtD
Erlotinib—Gastrointestinal pain—Estradiol—osteoporosis	0.000112	0.000588	CcSEcCtD
Erlotinib—Dermatitis—Zoledronate—osteoporosis	0.000112	0.000588	CcSEcCtD
Erlotinib—Headache—Zoledronate—osteoporosis	0.000112	0.000585	CcSEcCtD
Erlotinib—ORM1—bone marrow—osteoporosis	0.000111	0.0278	CbGeAlD
Erlotinib—Vomiting—Conjugated Estrogens—osteoporosis	0.000109	0.000571	CcSEcCtD
Erlotinib—Body temperature increased—Estradiol—osteoporosis	0.000109	0.000569	CcSEcCtD
Erlotinib—Abdominal pain—Estradiol—osteoporosis	0.000109	0.000569	CcSEcCtD
Erlotinib—Rash—Conjugated Estrogens—osteoporosis	0.000108	0.000567	CcSEcCtD
Erlotinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000108	0.000566	CcSEcCtD
Erlotinib—Headache—Conjugated Estrogens—osteoporosis	0.000107	0.000563	CcSEcCtD
Erlotinib—Nausea—Zoledronate—osteoporosis	0.000106	0.000554	CcSEcCtD
Erlotinib—ABL1—bone marrow—osteoporosis	0.000106	0.0264	CbGeAlD
Erlotinib—CYP1B1—uterus—osteoporosis	0.000105	0.0264	CbGeAlD
Erlotinib—Nausea—Conjugated Estrogens—osteoporosis	0.000102	0.000534	CcSEcCtD
Erlotinib—Asthenia—Estradiol—osteoporosis	9.85e-05	0.000516	CcSEcCtD
Erlotinib—Pruritus—Estradiol—osteoporosis	9.71e-05	0.000509	CcSEcCtD
Erlotinib—Diarrhoea—Estradiol—osteoporosis	9.39e-05	0.000492	CcSEcCtD
Erlotinib—Dizziness—Estradiol—osteoporosis	9.08e-05	0.000476	CcSEcCtD
Erlotinib—Vomiting—Estradiol—osteoporosis	8.73e-05	0.000457	CcSEcCtD
Erlotinib—Rash—Estradiol—osteoporosis	8.66e-05	0.000454	CcSEcCtD
Erlotinib—Dermatitis—Estradiol—osteoporosis	8.65e-05	0.000453	CcSEcCtD
Erlotinib—Headache—Estradiol—osteoporosis	8.6e-05	0.000451	CcSEcCtD
Erlotinib—Nausea—Estradiol—osteoporosis	8.15e-05	0.000427	CcSEcCtD
Erlotinib—ABCG2—uterus—osteoporosis	7.84e-05	0.0196	CbGeAlD
Erlotinib—CYP1A1—uterus—osteoporosis	7.44e-05	0.0187	CbGeAlD
Erlotinib—ABCG2—bone marrow—osteoporosis	6.65e-05	0.0167	CbGeAlD
Erlotinib—ABCB1—uterus—osteoporosis	3.87e-05	0.00969	CbGeAlD
Erlotinib—ABCB1—bone marrow—osteoporosis	3.28e-05	0.00822	CbGeAlD
Erlotinib—CYP1A1—Metabolism—CYP27A1—osteoporosis	1.29e-05	0.000108	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MGLL—osteoporosis	1.29e-05	0.000108	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—osteoporosis	1.29e-05	0.000108	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IRS1—osteoporosis	1.28e-05	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGA—osteoporosis	1.26e-05	0.000105	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—IDH2—osteoporosis	1.26e-05	0.000105	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ACP5—osteoporosis	1.26e-05	0.000105	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO1—osteoporosis	1.26e-05	0.000105	CbGpPWpGaD
Erlotinib—ALB—Metabolism—IDH2—osteoporosis	1.26e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CA2—osteoporosis	1.25e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—OXCT1—osteoporosis	1.25e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ATIC—osteoporosis	1.25e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PNP—osteoporosis	1.25e-05	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—ADCY5—osteoporosis	1.24e-05	0.000104	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.24e-05	0.000103	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TPI1—osteoporosis	1.24e-05	0.000103	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PSMA5—osteoporosis	1.24e-05	0.000103	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PSMA2—osteoporosis	1.24e-05	0.000103	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—POMC—osteoporosis	1.24e-05	0.000103	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MGLL—osteoporosis	1.22e-05	0.000101	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6R—osteoporosis	1.21e-05	0.0001	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IRS2—osteoporosis	1.2e-05	9.98e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF1—osteoporosis	1.19e-05	9.9e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP27A1—osteoporosis	1.19e-05	9.88e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP19A1—osteoporosis	1.18e-05	9.85e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP27A1—osteoporosis	1.18e-05	9.82e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—POMC—osteoporosis	1.18e-05	9.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTHLH—osteoporosis	1.17e-05	9.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BMP2—osteoporosis	1.17e-05	9.77e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—LEP—osteoporosis	1.17e-05	9.76e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TPI1—osteoporosis	1.17e-05	9.74e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—P4HB—osteoporosis	1.17e-05	9.7e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRS2—osteoporosis	1.16e-05	9.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—osteoporosis	1.16e-05	9.64e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ACP5—osteoporosis	1.15e-05	9.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGB—osteoporosis	1.15e-05	9.56e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ACP5—osteoporosis	1.15e-05	9.55e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GAPDH—osteoporosis	1.14e-05	9.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AGER—osteoporosis	1.14e-05	9.5e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.14e-05	9.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ADCY5—osteoporosis	1.14e-05	9.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.13e-05	9.43e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ESR1—osteoporosis	1.12e-05	9.32e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—RAP1A—osteoporosis	1.11e-05	9.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FDPS—osteoporosis	1.11e-05	9.23e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PKM—osteoporosis	1.11e-05	9.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PSMA2—osteoporosis	1.11e-05	9.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PSMA5—osteoporosis	1.11e-05	9.23e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP19A1—osteoporosis	1.1e-05	9.19e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—P4HB—osteoporosis	1.1e-05	9.16e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—IDH2—osteoporosis	1.1e-05	9.15e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TGFB1—osteoporosis	1.1e-05	9.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—osteoporosis	1.09e-05	9.1e-05	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.08e-05	9e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GAPDH—osteoporosis	1.08e-05	8.99e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TGFB1—osteoporosis	1.08e-05	8.96e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TPI1—osteoporosis	1.07e-05	8.93e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TPI1—osteoporosis	1.07e-05	8.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—OXCT1—osteoporosis	1.06e-05	8.82e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CA2—osteoporosis	1.06e-05	8.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—RAP1A—osteoporosis	1.05e-05	8.76e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PGLS—osteoporosis	1.05e-05	8.75e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPD2—osteoporosis	1.05e-05	8.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ADCY5—osteoporosis	1.05e-05	8.74e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IRS1—osteoporosis	1.05e-05	8.71e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—IDH2—osteoporosis	1.04e-05	8.62e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP27A1—osteoporosis	1.03e-05	8.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CALCA—osteoporosis	1.03e-05	8.6e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MGLL—osteoporosis	1.03e-05	8.59e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	1.03e-05	8.55e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—osteoporosis	1.02e-05	8.53e-05	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—osteoporosis	1.02e-05	8.46e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRS1—osteoporosis	1.02e-05	8.46e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.01e-05	8.44e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.01e-05	8.42e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—P4HB—osteoporosis	1.01e-05	8.4e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—POMC—osteoporosis	1.01e-05	8.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ACP5—osteoporosis	1.01e-05	8.37e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP19A1—osteoporosis	1e-05	8.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—P4HB—osteoporosis	1e-05	8.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRS2—osteoporosis	9.95e-06	8.28e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GAPDH—osteoporosis	9.9e-06	8.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—osteoporosis	9.9e-06	8.24e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GAPDH—osteoporosis	9.85e-06	8.2e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6R—osteoporosis	9.83e-06	8.18e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP27A1—osteoporosis	9.74e-06	8.11e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.74e-06	8.1e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1—osteoporosis	9.69e-06	8.07e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ADCY5—osteoporosis	9.67e-06	8.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—osteoporosis	9.66e-06	8.04e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RAP1A—osteoporosis	9.65e-06	8.03e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GPX1—osteoporosis	9.64e-06	8.02e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ATIC—osteoporosis	9.62e-06	8e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PNP—osteoporosis	9.62e-06	8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RAP1A—osteoporosis	9.59e-06	7.98e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6R—osteoporosis	9.55e-06	7.95e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ACP5—osteoporosis	9.48e-06	7.89e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—osteoporosis	9.48e-06	7.89e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	9.47e-06	7.88e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—osteoporosis	9.45e-06	7.87e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	9.45e-06	7.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KL—osteoporosis	9.38e-06	7.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—osteoporosis	9.38e-06	7.8e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TPI1—osteoporosis	9.35e-06	7.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IRS2—osteoporosis	9.19e-06	7.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.18e-06	7.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—POMC—osteoporosis	9.15e-06	7.62e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—osteoporosis	9.09e-06	7.57e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ADCY5—osteoporosis	9.02e-06	7.51e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO1—osteoporosis	9e-06	7.49e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GPX1—osteoporosis	8.99e-06	7.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6R—osteoporosis	8.93e-06	7.43e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—osteoporosis	8.9e-06	7.4e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PSMA5—osteoporosis	8.87e-06	7.38e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PSMA2—osteoporosis	8.87e-06	7.38e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF1—osteoporosis	8.84e-06	7.36e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TPI1—osteoporosis	8.81e-06	7.33e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—P4HB—osteoporosis	8.79e-06	7.32e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—IDH2—osteoporosis	8.78e-06	7.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—osteoporosis	8.76e-06	7.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRS1—osteoporosis	8.69e-06	7.23e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GAPDH—osteoporosis	8.63e-06	7.18e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO1—osteoporosis	8.51e-06	7.08e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.41e-06	7e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RAP1A—osteoporosis	8.4e-06	6.99e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PSMA5—osteoporosis	8.38e-06	6.98e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PSMA2—osteoporosis	8.38e-06	6.98e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.37e-06	6.96e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—osteoporosis	8.31e-06	6.91e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—osteoporosis	8.3e-06	6.91e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—P4HB—osteoporosis	8.28e-06	6.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—osteoporosis	8.27e-06	6.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP27A1—osteoporosis	8.25e-06	6.87e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ADCY5—osteoporosis	8.21e-06	6.83e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GPX1—osteoporosis	8.18e-06	6.81e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—OXCT1—osteoporosis	8.18e-06	6.8e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CA2—osteoporosis	8.18e-06	6.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6R—osteoporosis	8.16e-06	6.79e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GAPDH—osteoporosis	8.13e-06	6.77e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ACP5—osteoporosis	8.03e-06	6.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IRS1—osteoporosis	8.02e-06	6.67e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MGLL—osteoporosis	7.97e-06	6.63e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.93e-06	6.6e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RAP1A—osteoporosis	7.92e-06	6.59e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO1—osteoporosis	7.8e-06	6.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO1—osteoporosis	7.75e-06	6.45e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PSMA2—osteoporosis	7.68e-06	6.39e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PSMA5—osteoporosis	7.68e-06	6.39e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PSMA5—osteoporosis	7.64e-06	6.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PSMA2—osteoporosis	7.64e-06	6.36e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—osteoporosis	7.55e-06	6.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6R—osteoporosis	7.53e-06	6.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TPI1—osteoporosis	7.46e-06	6.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADCY5—osteoporosis	7.35e-06	6.12e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—osteoporosis	7.3e-06	6.08e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—osteoporosis	7.26e-06	6.04e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	7.2e-06	5.99e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—osteoporosis	7.15e-06	5.95e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—osteoporosis	7.13e-06	5.93e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—osteoporosis	7.12e-06	5.93e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—osteoporosis	7.12e-06	5.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SPP1—osteoporosis	7.11e-06	5.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—osteoporosis	7.07e-06	5.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—P4HB—osteoporosis	7.02e-06	5.84e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GAPDH—osteoporosis	6.89e-06	5.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP19A1—osteoporosis	6.8e-06	5.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO1—osteoporosis	6.79e-06	5.65e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH2—osteoporosis	6.78e-06	5.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RAP1A—osteoporosis	6.71e-06	5.58e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PSMA5—osteoporosis	6.69e-06	5.57e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PSMA2—osteoporosis	6.69e-06	5.57e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—osteoporosis	6.64e-06	5.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS2—osteoporosis	6.43e-06	5.35e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO1—osteoporosis	6.4e-06	5.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	6.37e-06	5.3e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PSMA2—osteoporosis	6.31e-06	5.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PSMA5—osteoporosis	6.31e-06	5.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEP—osteoporosis	6.29e-06	5.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—osteoporosis	6.24e-06	5.19e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP19A1—osteoporosis	6.23e-06	5.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—osteoporosis	6.21e-06	5.17e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP19A1—osteoporosis	6.2e-06	5.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ACP5—osteoporosis	6.2e-06	5.16e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—osteoporosis	6.04e-06	5.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ESR1—osteoporosis	6.01e-06	5e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ADCY5—osteoporosis	5.88e-06	4.89e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX1—osteoporosis	5.86e-06	4.88e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.85e-06	4.87e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—osteoporosis	5.83e-06	4.85e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	5.81e-06	4.84e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TPI1—osteoporosis	5.76e-06	4.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS1—osteoporosis	5.62e-06	4.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADCY5—osteoporosis	5.56e-06	4.62e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—osteoporosis	5.54e-06	4.61e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP19A1—osteoporosis	5.43e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO1—osteoporosis	5.42e-06	4.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—P4HB—osteoporosis	5.42e-06	4.51e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—osteoporosis	5.41e-06	4.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—osteoporosis	5.41e-06	4.5e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—osteoporosis	5.37e-06	4.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMA2—osteoporosis	5.34e-06	4.45e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMA5—osteoporosis	5.34e-06	4.45e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GAPDH—osteoporosis	5.32e-06	4.42e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—osteoporosis	5.3e-06	4.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6R—osteoporosis	5.27e-06	4.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—osteoporosis	5.2e-06	4.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RAP1A—osteoporosis	5.18e-06	4.31e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP19A1—osteoporosis	5.12e-06	4.26e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—osteoporosis	5.11e-06	4.25e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADCY5—osteoporosis	5.09e-06	4.24e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—osteoporosis	5.08e-06	4.22e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADCY5—osteoporosis	5.06e-06	4.21e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—osteoporosis	5.05e-06	4.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—osteoporosis	4.68e-06	3.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—osteoporosis	4.66e-06	3.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—osteoporosis	4.46e-06	3.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—osteoporosis	4.45e-06	3.71e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADCY5—osteoporosis	4.44e-06	3.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—osteoporosis	4.42e-06	3.68e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—osteoporosis	4.38e-06	3.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—osteoporosis	4.34e-06	3.61e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—osteoporosis	4.33e-06	3.6e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—osteoporosis	4.25e-06	3.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO1—osteoporosis	4.19e-06	3.48e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADCY5—osteoporosis	4.18e-06	3.48e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—osteoporosis	4.17e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMA5—osteoporosis	4.12e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMA2—osteoporosis	4.12e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—osteoporosis	4.09e-06	3.4e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—osteoporosis	4.08e-06	3.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—osteoporosis	3.98e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—osteoporosis	3.85e-06	3.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—osteoporosis	3.75e-06	3.12e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—osteoporosis	3.73e-06	3.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—osteoporosis	3.63e-06	3.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADCY5—osteoporosis	3.54e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—osteoporosis	3.53e-06	2.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—osteoporosis	3.36e-06	2.79e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	3.35e-06	2.78e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—osteoporosis	3.26e-06	2.72e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—osteoporosis	3.26e-06	2.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—osteoporosis	3.13e-06	2.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—osteoporosis	3.12e-06	2.59e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—osteoporosis	3.08e-06	2.56e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADCY5—osteoporosis	2.73e-06	2.28e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—osteoporosis	2.72e-06	2.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—osteoporosis	2.61e-06	2.17e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—osteoporosis	2.51e-06	2.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—osteoporosis	2.35e-06	1.96e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—osteoporosis	2.01e-06	1.67e-05	CbGpPWpGaD
